Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Details : Through the acquisition, Eton gains access to an abbreviated new drug application for Nitisinone Capsules via Oakrum. Nitisinone is FDA approved or the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine ...
Product Name : Nitisinone-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 10, 2023
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition